Candida glabrata: An important fungal pathogen for the 21st century

Paul L. Fidel, Jose Antonio Vazquez, Jack D. Sobel

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Although Candida glabrata has been viewed as a relatively nonpathogenic saprophyte, it is now considered an important fungal pathogen. The reason is the widespread use of immunosuppressive therapy, together with broad-spectrum antimycotic therapy to which the organism may be resistant. This article reviews the biology, epidemiology, pathogenesis, clinical spectrum of infection, and antifungal resistance of this yeast. Infections with C. glabrata are likely to increase as antifungal agents continue to be used; therefore, further studies of pathogenesis, host responses, and antifungal resistance mechanisms are needed.

Original languageEnglish (US)
Pages (from-to)171-176
Number of pages6
JournalClinical Microbiology Newsletter
Volume23
Issue number22
DOIs
StatePublished - Nov 15 2001
Externally publishedYes

Fingerprint

Candida glabrata
Antifungal Agents
Immunosuppressive Agents
Infection
Epidemiology
Yeasts
Therapeutics

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Candida glabrata : An important fungal pathogen for the 21st century. / Fidel, Paul L.; Vazquez, Jose Antonio; Sobel, Jack D.

In: Clinical Microbiology Newsletter, Vol. 23, No. 22, 15.11.2001, p. 171-176.

Research output: Contribution to journalArticle

@article{28fd0603d84c4386a8e8a90fe1f7b642,
title = "Candida glabrata: An important fungal pathogen for the 21st century",
abstract = "Although Candida glabrata has been viewed as a relatively nonpathogenic saprophyte, it is now considered an important fungal pathogen. The reason is the widespread use of immunosuppressive therapy, together with broad-spectrum antimycotic therapy to which the organism may be resistant. This article reviews the biology, epidemiology, pathogenesis, clinical spectrum of infection, and antifungal resistance of this yeast. Infections with C. glabrata are likely to increase as antifungal agents continue to be used; therefore, further studies of pathogenesis, host responses, and antifungal resistance mechanisms are needed.",
author = "Fidel, {Paul L.} and Vazquez, {Jose Antonio} and Sobel, {Jack D.}",
year = "2001",
month = "11",
day = "15",
doi = "10.1016/S0196-4399(01)80058-1",
language = "English (US)",
volume = "23",
pages = "171--176",
journal = "Clinical Microbiology Newsletter",
issn = "0196-4399",
publisher = "Elsevier Inc.",
number = "22",

}

TY - JOUR

T1 - Candida glabrata

T2 - An important fungal pathogen for the 21st century

AU - Fidel, Paul L.

AU - Vazquez, Jose Antonio

AU - Sobel, Jack D.

PY - 2001/11/15

Y1 - 2001/11/15

N2 - Although Candida glabrata has been viewed as a relatively nonpathogenic saprophyte, it is now considered an important fungal pathogen. The reason is the widespread use of immunosuppressive therapy, together with broad-spectrum antimycotic therapy to which the organism may be resistant. This article reviews the biology, epidemiology, pathogenesis, clinical spectrum of infection, and antifungal resistance of this yeast. Infections with C. glabrata are likely to increase as antifungal agents continue to be used; therefore, further studies of pathogenesis, host responses, and antifungal resistance mechanisms are needed.

AB - Although Candida glabrata has been viewed as a relatively nonpathogenic saprophyte, it is now considered an important fungal pathogen. The reason is the widespread use of immunosuppressive therapy, together with broad-spectrum antimycotic therapy to which the organism may be resistant. This article reviews the biology, epidemiology, pathogenesis, clinical spectrum of infection, and antifungal resistance of this yeast. Infections with C. glabrata are likely to increase as antifungal agents continue to be used; therefore, further studies of pathogenesis, host responses, and antifungal resistance mechanisms are needed.

UR - http://www.scopus.com/inward/record.url?scp=0035890147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035890147&partnerID=8YFLogxK

U2 - 10.1016/S0196-4399(01)80058-1

DO - 10.1016/S0196-4399(01)80058-1

M3 - Article

AN - SCOPUS:0035890147

VL - 23

SP - 171

EP - 176

JO - Clinical Microbiology Newsletter

JF - Clinical Microbiology Newsletter

SN - 0196-4399

IS - 22

ER -